Iocetamic Acid

Summary

Iocetamic Acid (CHEMBL1200770) is an approved small molecule (ATC V08AC07).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AC07
• Chemistry: 613.96 Da · C12H13I3N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200770
Name	Iocetamic Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	27648
ATC	V08AC07
Molecular formula	C12H13I3N2O3
Molecular weight	613.96
InChIKey	GSVQIUGOUKJHRC-UHFFFAOYSA-N

SMILES: CC(CN(C1=C(C=C(C(=C1I)N)I)I)C(=O)C)C(=O)O

IUPAC name: 3-(N-acetyl-3-amino-2,4,6-triiodoanilino)-2-methylpropanoic acid

Also known as: Acide iocetamique, Acido iocetamico, Cholebrine, Iocetamic acid, MP-620, SID56463701, IOCETAMIC ACID, SID144204131, IOCETAMIC-ACID, iocetamic-acid, DRC-1201

Patent coverage: 481 distinct patent families (1,867 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Beta-lactamase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P00811	5.55	Potency	2818	nM	CHEMBL_ACT_4668248

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).